Christine J. Guico-Pabia, MD, MBA, MPH
Article
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d
June 4, 2015
The authors of this article conducted a post hoc analysis of data from 8 short-term and 1 longer-term double-blind, placebo-controlled studies of patients with major depressive disorder treated with...
Article
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder
February 26, 2015
In this article by McIntyre and colleagues, relapse rates and predictors of relapse were evaluated in 2 randomized, placebo-controlled trials of desvenlafaxine for major depressive disorder.
Article
Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder
February 5, 2015
Here, review results from a post hoc analysis that evaluated the tolerability of long-term desvenlafaxine for major depressive disorder at discontinuation using a taper regimen compared with abrupt discontinuation.Â
Article
Improving Quality of Depression Care Using Organized Systems of Care: A Review of the Literature
February 10, 2011
The authors of this article attempt to establish the need for a chronic disease management strategy for major depressive disorder, discuss the challenges involved in implementing guideline-level treatment, and...
Article
Beyond Symptomatic Improvement: Assessing Real-World Outcomes in Patients With Major Depressive Disorder
April 15, 2010
The objective of this systematic review was to measure the negative impact that MDD has on quality of life, disability, and work, family, and overall psychosocial functioning. Available scales...
